Uyanga Tsedev
Chief Scientific Officer & Co-Founder Gensaic
Uyanga Tsedev is the Chief Scientific Officer and Co-Founder of Gensaic, a biotechnology company pioneering novel gene delivery platforms. A seasoned scientist with over a decade of experience, she leverages her deep expertise in biomolecular engineering and materials science to advance therapeutic development. Dr. Tsedev earned her PhD and MSc from the Massachusetts Institute of Technology’s prestigious Biomolecular Materials Group, led by Professor Angela Belcher. Prior to her work at MIT, she conducted research in tissue engineering and drug delivery at Harvard University, laying a strong foundation for her innovative work in creating transformative genetic medicines.
Seminars
Wednesday 28th January 2026
Engineering a Dual-Targeting siRNA Therapeutic with AI-Designed Ligands to Treat the Underlying Biology of Sarcopenia
9:30 am
- Introducing a novel protein-conjugated siRNA modality for muscle that enables targeted delivery to skeletal muscle to overcome limitations of current antibody-based inhibitors, while avoiding off-target tissues
- Leveraging dual-targeting to silence redundant nodes in the inhibitory signalling pathway of muscle growth, moving beyond single-target inhibition to achieve functional recovery
- Demonstrating in vivo delivery, potent target knockdown, and significant functional improvement in models of muscle wasting
